BG-1805 / Hedy Group 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BG-1805 / Hedy Group
NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
24
RoW
BG1805
Guangzhou Bio-gene Technology Co., Ltd
Leukemia, Myeloid, Acute
03/25
07/25
NCT06347458: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

Not yet recruiting
1
24
NA
BG1805
Guangzhou Bio-gene Technology Co., Ltd
Leukemia, Acute Myeloid Leukemia
04/27
08/27
ChiCTR2300076953: A Single-Arm, Dose-Escalation and Dose-Expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Not yet recruiting
1
24
 
CAR-T
The First Affiliated Hospital, Zhejiang University School of Medicine; Guangzhou Bio-gene Technology Co., Ltd, Sponsor
Acute Myeloid Leukemia
 
 
ChiCTR2200060127: A single-arm, dose-escalation and dose-expansion phase I clinical study to evaluate the tolerability, safety and preliminary efficacy of BG1805 injection in the treatment of relapsed or refractory acute myeloid leukemia

Not yet recruiting
N/A
24
 
CAR-T; CAR-T
The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University, Guangzhou Bio-gene Technology Co., Ltd.
relapsed or refractory acute myeloid leukemia(r/r AML)
 
 

Download Options